Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1966 2
1967 5
1968 1
1969 5
1970 5
1971 12
1972 8
1973 21
1974 11
1975 16
1976 15
1977 13
1978 19
1979 10
1980 11
1981 13
1982 8
1983 8
1984 8
1985 12
1986 8
1987 11
1988 14
1989 15
1990 11
1991 11
1992 11
1993 6
1994 4
1995 3
1996 10
1997 11
1998 12
1999 13
2000 13
2001 9
2002 15
2003 17
2004 19
2005 27
2006 44
2007 43
2008 57
2009 51
2010 50
2011 69
2012 77
2013 65
2014 76
2015 136
2016 194
2017 199
2018 192
2019 90
2020 10
Text availability
Article attribute
Article type
Publication date

Search Results

1,671 results
Results by year
Filters applied: . Clear all
Page 1
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Afdhal N, et al. N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11. N Engl J Med. 2014. PMID: 24725239 Free article. Clinical Trial.
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators. Kowdley KV, et al. N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10. N Engl J Med. 2014. PMID: 24720702 Free article. Clinical Trial.
Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania.
Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, Kataraihya JB, Mandike R, Mkude S, Chacky F, Njau R, Premji Z, Lemnge MM, Warsame M, Menard D, Kabanywanyi AM. Kakolwa MA, et al. Malar J. 2018 Oct 17;17(1):369. doi: 10.1186/s12936-018-2524-x. Malar J. 2018. PMID: 30333022 Free PMC article.
Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice.
Vartiainen V, Raula J, Bimbo LM, Viinamäki J, Backman JT, Ugur N, Kauppinen E, Sutinen E, Joensuu E, Koli K, Myllärniemi M. Vartiainen V, et al. Int J Pharm. 2018 Jun 10;544(1):121-128. doi: 10.1016/j.ijpharm.2018.04.019. Epub 2018 Apr 12. Int J Pharm. 2018. PMID: 29655797
2‑Acetylaminofluorene.
National Toxicology Program. National Toxicology Program. Rep Carcinog. 2011;12:24-5. Rep Carcinog. 2011. PMID: 21829238 Free article. No abstract available.
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Landier J, Parker DM, Thu AM, Lwin KM, Delmas G, Nosten FH; Malaria Elimination Task Force Group. Landier J, et al. Lancet. 2018 May 12;391(10133):1916-1926. doi: 10.1016/S0140-6736(18)30792-X. Epub 2018 Apr 24. Lancet. 2018. PMID: 29703425 Free PMC article. Clinical Trial.
1,671 results
Jump to page
Feedback